#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13170	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2083	629.4	0	.	n	.	0	C850T	SNP	850	850	C	1113	1113	T	795	T,C	758,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13170	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2083	629.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	1713	1713	T	733	T	665	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13170	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2083	629.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1447	1447	C	759	C	709	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24174	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3629	664.1	0	.	n	.	0	T695C	SNP	695	695	T	1068	1068	C	784	C	729	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24174	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3629	664.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2344	2344	C	776	C,T	714,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24174	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3629	664.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2418	2418	A	772	A	729	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24174	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3629	664.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	2970	2970	C	751	C,T	697,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	16	12	blaTEM	861	207	100.0	blaTEM.l15.c4.ctg.1	207	3.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	1890	folP	852	852	99.88	folP.l15.c4.ctg.1	1443	130.4	0	.	p	.	0	A204V	NONSYN	610	612	GCA	912	914	GTA	143;143;144	G;T,C;A	136;133,1;137	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	1890	folP	852	852	99.88	folP.l15.c4.ctg.1	1443	130.4	1	SNP	p	R228S	0	.	.	682	684	CGC	984	986	CGC	181;184;182	C,A;G;C	166,1;170;167	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4560	gyrA	2751	2751	99.82	gyrA.l15.c30.ctg.1	3384	134.4	1	SNP	p	S91F	0	.	.	271	273	TCC	588	590	TCC	159;155;154	T;C;C	147;139;140	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4560	gyrA	2751	2751	99.82	gyrA.l15.c30.ctg.1	3384	134.4	1	SNP	p	D95G	0	.	.	283	285	GAC	600	602	GAC	160;160;163	G;A;C	142;144;148	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4560	gyrA	2751	2751	99.82	gyrA.l15.c30.ctg.1	3384	134.4	1	SNP	p	D95N	0	.	.	283	285	GAC	600	602	GAC	160;160;163	G;A;C	142;144;148	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	1524	mtrR	633	633	99.68	mtrR.l15.c30.ctg.1	1288	117.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	718	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	917	77.9	0	.	n	.	0	G33.	DEL	33	33	G	342	342	G	162	G	151	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4366	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2881	151.0	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1591	1593	GCA	168;167;168	G;C;A	152;148;146	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4366	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2881	151.0	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2074	2076	ATT	187;189;189	A,T;T;T	161,1;165;165	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4366	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2881	151.0	0	.	p	.	0	V646A	NONSYN	1936	1938	GTG	2224	2226	GCG	163;164;163	G;C;G	150;151;151	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4366	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2881	151.0	1	SNP	p	D86N	0	.	.	256	258	GAC	544	546	GAC	175;173;174	G;A;C	165;162;164	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4366	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2881	151.0	1	SNP	p	S87W	0	.	.	259	261	AGT	547	549	AGT	174;175;177	A;G;T	162;162;162	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4366	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2881	151.0	1	SNP	p	S87I	0	.	.	259	261	AGT	547	549	AGT	174;175;177	A;G;T	162;162;162	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4366	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2881	151.0	1	SNP	p	S87R	0	.	.	259	261	AGT	547	549	AGT	174;175;177	A;G;T	162;162;162	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4366	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2881	151.0	1	SNP	p	S88P	0	.	.	262	264	TCC	550	552	TCC	179;181;185	T;C;C	167;166;169	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3948	parE	1986	1986	99.85	parE.l15.c30.ctg.1	2504	156.5	0	.	p	.	0	V89A	NONSYN	265	267	GTC	482	484	GCC	201;198;196	G;C;C	183;186;180	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3948	parE	1986	1986	99.85	parE.l15.c30.ctg.1	2504	156.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1445	1447	GGC	199;200;200	G;G;C	181;182;179	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.45.001	penA.45.001	1	1	27	3856	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2218	172.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1170	1172	GCA	243;244;246	G;C;A	227;227;231	penA.45.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3856	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2218	172.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1173	1175	ATC	252;251;252	A;T;C	235;236;234	penA.45.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3856	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2218	172.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1185	1187	GTG	254;257;254	G;T;G	232;234;229	penA.45.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3856	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2218	172.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1185	1187	GTG	254;257;254	G;T;G	232;234;229	penA.45.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3856	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2218	172.4	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1686	1688	ACC	194;194;194	A;C,T;C	178;179,1;179	penA.45.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3856	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2218	172.4	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1740	1742	GCG	194;196;195	G;C;G	165;154;160	penA.45.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3856	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2218	172.4	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1740	1742	GCG	194;196;195	G;C;G	165;154;160	penA.45.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3856	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2218	172.4	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1863	1865	GGT	166;166;166	G;G;T	150;153;151	penA.45.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3856	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2218	172.4	1	SNP	p	G545S	0	.	.	1633	1635	GGC	1872	1874	GGC	173;172;174	G;G;C	154;154;156	penA.45.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3856	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2218	172.4	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1890	1892	CCG	170;172;170	C;C;G	117;141;125	penA.45.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5066	ponA	2397	2397	99.92	ponA.l15.c4.ctg.1	3084	163.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2138	porA	1146	1146	99.65	porA.l15.c17.ctg.1	1609	131.6	0	.	p	.	0	S22G	NONSYN	64	66	AGC	285	287	GGC	162;159;161	G;G;C	150;144;146	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2138	porA	1146	1146	99.65	porA.l15.c17.ctg.1	1609	131.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	467	467	C	167	C	153	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	T87A	NONSYN	259	261	ACT	493	495	GCT	202;203;205	G;C;T	187;188;186	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	T89S	NONSYN	265	267	ACC	499	501	AGC	203;202;199	A;G;C,A,T	183;182;177,2,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	.	MULTIPLE	358	359	AA	591	592	CG	203;202	C;G	187;187	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	.	MULTIPLE	361	362	GA	594	596	CAG	201;198;197	C,G;A;G	187,1;185;184	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	N122K	NONSYN	364	366	AAC	598	600	AAA	199;200;200	A;A;A	184;186;186	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	K143E	NONSYN	427	429	AAA	661	663	GAA	178;175;175	G;A;A	160;158;159	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	V151A	NONSYN	451	453	GTA	685	687	GCA	184;188;189	G;C;A	178;182;181	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	T213S	NONSYN	637	639	ACA	871	873	TCA	211;212;207	T;C;A,T	197;199;194,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	991	993	CAA	206;207;204	C,A;A;A	199,1;202;200	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	.	INDELS	760	762	ACA	995	999	ATCAA	207;206;208;208;207	A;T;C;A;A	202;200;202;203;202	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	.	INDELS	763	764	TG	1002	1004	AGT	208;209;210	A;G;T	202;202;203	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1009	1011	GAT	204;202;202	G,T;A;T	196,1;197;195	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1117	1119	AGT	273;272;266	A,G;G,A;T	252,2;252,1;246	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1123	1125	GAC	264;266;262	G,A;A;C	245,3;249;245	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1126	1128	TAC	260;261;258	T,C;A;C	246,2;248;246	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	1	SNP	p	G120K	1	.	.	358	360	AAG	591	593	CGG	203;202;199	C;G;G	187;187;186	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	1	SNP	p	D121N	0	.	.	361	363	GAC	594	597	CGC	201;197;197	C,G;G;C	187,1;184;182	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2650	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1425	184.6	1	SNP	p	A121D	1	.	.	361	363	GAC	594	597	CGC	201;197;197	C,G;G;C	187,1;184;182	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	9886	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4709	209.2	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1906	1908	CAT	221;223;223	C;A;T	197;197;197	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1064	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1083	97.7	1	SNP	p	V57M	0	.	.	169	171	GTG	558	560	GTG	233;232;230	G;T;G	211;209;208	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
